ArticleHeart rhythm2020
Real-world experience of leadless left ventricular endocardial cardiac resynchronization therapy: A multicenter international registry of the WiSE-CRT pacing system.
Article in Heart rhythm, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02610673 (WiCS-LV Post Market Surveillance Registry), which is not on this map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
WiCS-LV Post Market Surveillance Registry
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Leadless ultrasound-based LV endocardial pacing for CRT: systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- WiSE CRT Is Beneficial for Heart Failure Patients as a Rescue Therapy: Evidence From a Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Efficacy of leadless left ventricular endocardial stimulation for non-responders to cardiac resynchronization therapy.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Observational
- Mitigations for extra stimuli of the left ventricular endocardium with the WiSE-CRT System.International journal of cardiology. Heart & vasculature · 2026Article
- Era of Synchronized Physiologic Leadless Pacing: A Novel Approach to Cardiac Pacing and Ongoing Development.Journal of clinical medicine · 2026Review
- [Endocardial left ventricular pacing in 2025].Herzschrittmachertherapie & Elektrophysiologie · 2025Review
- Evolution of leadless pacemaker technology.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Potential applications of ultrasound-based leadless endocardial pacing in adult congenital heart disease.Heart rhythm · 2025Article
- Leadless Pacing: Current Status and Ongoing Developments.Micromachines · 2025Review
- Article
- Beyond Medical Therapy-An Update on Heart Failure Devices.Journal of cardiovascular development and disease · 2024Review
- Computational Modelling Enabling In Silico Trials for Cardiac Physiologic Pacing.Journal of cardiovascular translational research · 2024Review
- Cost-effectiveness analysis of leadless cardiac resynchronization therapy.Journal of cardiovascular electrophysiology · 2023Article
- Article
- Cardiac stereotactic radiotherapy for refractory ventricular tachycardia in a patient with wireless left ventricular endocardial stimulation system.HeartRhythm case reports · 2023Article
- The evolving state of cardiac resynchronization therapy and conduction system pacing: 25 years of research at EP Europace journal.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Review
- Cardiac resynchronization therapy: present and future.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Proarrhythmic effect of bipolar epicardial left ventricular stimulation in CRT resolved maintaining biventricular pacing with unipolar-cathodical configuration: A peculiar case report.Journal of arrhythmia · 2023Article
- Leadless Cardiac Pacing: New Horizons.Cardiology and therapy · 2023Review
- Leadless Pacing: Therapy, Challenges and Novelties.Arrhythmia & electrophysiology review · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 14 institutions in 8 countries.
Funding
Abstract
backgroundBiventricular endocardial pacing (BiV ENDO) is a therapy for heart failure patients who cannot receive transvenous epicardial cardiac resynchronization therapy (CRT) or have not responded adequately to CRT. BiV ENDO CRT can be delivered by a new wireless LV ENDO pacing system (WiSE-CRT system; EBR Systems, Sunnyvale, CA), without the requirement for lifelong anticoagulation.
objectiveThe purpose of this study was to assess the safety and efficacy of the WiSE-CRT system during real-world clinical use in an international registry.
methodsData were prospectively collected from 14 centers implanting the WiSE-CRT system as part of the WiCS-LV Post Market Surveillance Registry. (ClinicalTrials.gov Identifier: NCT02610673).
resultsNinety patients from 14 European centers underwent implantation with the WiSE-CRT system. Patients were predominantly male, age 68.2 ± 10.5 years, left ventricular ejection fraction 30.6% ± 8.9%, mean QRS duration 180.7 ± 27.0 ms, and 40% with ischemic etiology. Successful implantation and delivery of BiV ENDO pacing was achieved in 94.4% of patients. Acute (<24 hours), 1- to 30-day, and 1- to 6-month complications rates were 4.4%, 18.8%, and 6.7%, respectively. Five deaths (5.6%) occurred within 6 months (3 procedure related). Seventy percent of patients had improvement in heart failure symptoms.
conclusionBiV ENDO pacing with the WiSE-CRT system seems to be technically feasible, with a high success rate. Three procedural deaths occurred during the study. Procedural complications mandate adequate operator training and implantation at centers with immediately available cardiothoracic and vascular surgical support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.